Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

Table 1 Currently approved biologic treatments for inflammatory bowel diseases[16,117,118]

Medication	Route of administration (IV, SC, PO)	Approved dose
Infliximab	IV	Induction: 5-10 mg/kg (weeks 0, 2, and 6) Maintenance: 5-10 mg/kg every 4-8 wk
Adalimumab	SC	Induction: 160 mg (week 0), 80 mg (week 2) Maintenance: 40 mg every 7-14 d
Golimumab	SC	Induction: 200 mg (week 0), 100 mg (week 2) Maintenance: 100 mg every 4 wk
Certolizumab	SC	Induction: 400 mg (weeks 0, 2, and 4) Maintenance: 400 mg every 4 wk
Vedolizumab	IV	Induction: 300 mg (weeks 0, 2, and 6) Maintenance: 300 mg every 4-8 wk
Ustekinumab	IV SC	Induction: < 55 kg: 260 mg 55-85 kg: 390 mg > 85 kg: 520 mg Maintenance: 90 mg every 8 wk